Latest filing published 08 Apr 2024 for NGM Biopharmaceuticals INC.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David J. Woodhouse: trading record in brief
David J. Woodhouse is a declared insider of NGM Biopharmaceuticals Inc (chief executive), with filings sourced from SEC (Form 4). In total, 8 filings cover trades dated from 18 November 2021 to 5 April 2024.
No open-market purchase appears, only 1 sale worth €265k. Outside the open market, there are 2 share grants and 3 option exercises.
The record was last updated on 8 April 2024 with a transaction in NGM Biopharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to David J. Woodhouse
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 23,993 sharesCommon StockSEC:0000950170-24-042609:0
- 13,032 shares@ US$1.344.1% of flowCommon StockSEC:0001415889-24-001541:0
- 127,200 shares0Common StockSEC:0001209191-23-016396:0
- 12,987 shares@ US$7.7043.3% of flowCommon StockSEC:0001209191-21-071613:0
- 15,000 shares@ US$7.5448.9% of flowCommon StockSEC:0001209191-21-065973:0
5 of 5 declarations